J&J settles by paying $50M to Emergent for their violation of FDA regulations in manufacturing J&J covid vaccine.

You read it correctly.

On July 2, 2020, J&J (Janssen), then part of the Operation Warp Speed, entered into an agreement with Emergent BioSolutions for the manufacture of its viral vector-based COVID-19 vaccine.

However, Emergent was fou…